TrialScientific reports2023

Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.

Dateng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.